2021 American Transplant Congress
Obesity Impacts Acute Rejection but Not Allograft Function Improvement in the Setting of Belatacept Conversion
University of Illinois at Chicago, Chicago, IL
*Purpose: There is limited data regarding belatacept conversion in obese patients as an alternative to calcineurin inhibitor (CNI) immunosuppression. Pharmacokinetic (PK) data suggests increasing clearance…2021 American Transplant Congress
Evaluation of Empiric Extended-Release Tacrolimus Dosing in Adult Kidney Transplant Recipients
Pharmacy, NewYork-Presbyterian Hospital, New York, NY
*Purpose: Envarsus XR® (extended-release [XR] tacrolimus) is the standard of care tacrolimus formulation at our center for de novo maintenance immunosuppression in adult kidney transplant…2021 American Transplant Congress
Predictors of Postoperative Atrial Fibrillation in an Urban, Obese Adult Renal Transplant Population
University of Illinois at Chicago, Chicago, IL
*Purpose: Postoperative atrial fibrillation (POAF) is a common surgical complication. Renal transplant (RT) recipients possess risk factors that may lead to a higher incidence of…2021 American Transplant Congress
Attitudes of Obese Kidney Transplant Candidates Towards Bariatric Surgery
Surgery, University of Illinois Hospital & Health Sciences System, Chicago, IL
*Purpose: Obesity is an epidemic in the US and increasingly prevalent in kidney transplant candidates. Surgical weight-loss interventions are effective and reduce transplant-related complications. They…2021 American Transplant Congress
Outcomes of Simultaneous Kidney-Pancreas Transplantation in Patients with Type-I and Type-II Diabetes Mellitus
*Purpose: UNOS approved simultaneous kidney-pancreas transplantation (SKPT) for type-II diabetes mellitus (DM) in Oct 2014. There is limited data comparing outcomes of SKPT in type-I…2021 American Transplant Congress
Ganciclovir Therapeutic Drug Monitoring in Obese Adults Patients – Opportunity for Clinical Utility
*Purpose: Ganciclovir (GCV) is the drug of choice for the treatment of cytomegalovirus (CMV) infection; optimal dosing of GCV in the obese patient population is…2021 American Transplant Congress
Body Mass Index >35 Does Not Impact Kidney Transplant Outcomes or Health Related Quality of Life Despite BMI Class or Recipient Race
*Purpose: Kidney transplant [KTx] in recipients with BMI > 35 remains controversial and has not often been studied in recipients with BMI >40. There is…2021 American Transplant Congress
Taurodeoxycholic Acid and L-valine Ameliorate Macrophage Driven Alloimmunity in Obese Transplant Recipients
*Purpose: Obesity initiates a chronic inflammatory network linked to more frequent perioperative complications and increased acute rejection rates after organ transplantation. Clinically, morbidly obese transplant…2021 American Transplant Congress
Association of Obesity and Early Post Kidney Transplantation Complications
Columbia University Irving Medical Center, New York, NY
*Purpose: Although the prevalence of obesity among kidney transplant recipients is rising, there continues to be reluctance to waitlist obese candidates. We sought to determine…2021 American Transplant Congress
Does the NSQIP-Transplant Experience Demonstrate That Obese Kidney Transplant Recipients are Still at Increased Risk for Surgical Site Infections?
*Purpose: The National Surgical Quality Improvement Program for Transplant (NSQIP-T) was designed to track surgical outcomes in adult liver and kidney transplants (KTX). The Pilot…
- 1
- 2
- 3
- …
- 21
- Next Page »